Opportunities and Challenges in the Therapeutic and CDMO Markets

New Biologics and Advanced Therapies

The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.

With this backdrop, contract development and manufacturing organizations (CDMOs) play a pivotal role in enabling sponsor companies to bring groundbreaking therapies to patients.

Our Transaction Advisory experts have analyzed the CDMO industry trends, M&A activities, and projected growth. Have a look at the analysis in the article “New Biologics and Advanced Therapies: Opportunities and Challenges in the Therapeutic and CDMO Markets” published in CHEManager.